# Characteristics, Treatment and Healthcare Resource Utilisation in Patients diagnosed with Neuropathic or Chronic Pain Using Primary Care Electronic Health Records in the United Kingdom (UK)

**First published:** 29/06/2022

**Last updated:** 23/04/2024

Study Planned

## Administrative details

**EU PAS number**

EUPAS47913

**Study ID**

49167

**DARWIN EU® study**

No

**Study countries**

United Kingdom

**Study status**

Planned

# Research institutions and networks

## Institutions

### OPEN Health

**First published:** 01/02/2024

**Last updated:** 01/02/2024

**Institution**

## Contact details

**Study institution contact**

David Price dprice@opri.sg

**Study contact**

dprice@opri.sg

**Primary lead investigator**

David Price

**Primary lead investigator**

## Study timelines

**Date when funding contract was signed**

Actual: 13/06/2022

**Study start date**
Planned: 31/08/2022

**Date of final study report**
Planned: 31/12/2022

## Sources of funding

- Pharmaceutical company and other private sector

## More details on funding

Grunenthal Limited

## Regulatory

**Was the study required by a regulatory body?**

No

**Is the study required by a Risk Management Plan (RMP)?**

Not applicable

# Methodological aspects

## Study type

## Study type list

**Study type:**

Non-interventional study

---

**Scope of the study:**

Disease epidemiology

**Main study objective:**

To describe the characteristics and treatments for patients with a diagnosis of peripheral neuropathic pain, diabetic neuropathic pain, trigeminal neuralgia or chronic intractable pain in primary care in the UK.

## Study Design

**Non-interventional study design**

Cohort

## Study drug and medical condition

**Medical condition to be studied**

Neuralgia

Pain

## Population studied

**Age groups**

- Adults (18 to < 46 years)
- Adults (46 to < 65 years)

- Adults (65 to < 75 years)
- Adults (75 to < 85 years)
- Adults (85 years and over)

---

**Estimated number of subjects**

11.700

## Study design details

**Outcomes**

To estimate the HCRU and associated costs of managing patients with peripheral neuropathic pain, diabetic neuropathic pain, trigeminal neuralgia or chronic intractable pain in the UK.

---

**Data analysis plan**

Descriptive Analyses All analyses will be descriptive and carried out using Microsoft SQL, R, Stata 14 (StataCorp LLC) and Microsoft Excel. Treatment, HCRU and costs will be summarised aggregating available patients' follow-up as follows: a) By calendar year (e.g. 2017-2018) b) By 3-calendar years of data aggregated (e.g. 2017-2020) c) For the calendar years April 2019 – March 2020 and April 2020 – March 2021 separately to describe the pre- and post-COVID-19 periods. d) By number of patient-years since index pain diagnosis, at 1, 2, and 3 patient-year post-index date

## Data management

## ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

# Data sources

**Data source(s)**

Optimum Patient Care Research Database

**Data sources (types)**

Electronic healthcare records (EHR)

# Use of a Common Data Model (CDM)

**CDM mapping**

No

# Data quality specifications

**Check conformance**

Unknown

**Check completeness**

Unknown

**Check stability**

Unknown

**Check logical consistency**

Unknown

# Data characterisation

**Data characterisation conducted**

No